Navigation Links
Virus infection supports organ acceptance
Date:6/26/2014

This news release is available in German.

Over 150 million people throughout the world suffer from chronic infection with the hepatitis C virus (HCV), which causes massive damage to the liver. Advanced liver diseases often necessitate liver transplants. In the new clinical study Dr. Felix Bohne and his colleagues studied together with Prof. Alberto Snchez-Fueyo from King's College London 34 hepatitis C patients at the Liver Unit of the University Hospital Clnic de Barcelona who had received new livers.

The researchers had two objectives here: first, they wanted to gain a better understanding of the mechanisms that enable the body's own immune system to tolerate the new organ despite the HCV infection; second, they were looking for factors that could act as biomarkers for tolerance in the patients.

"If tolerance could be reliably predicted based on certain markers, many patients could stop taking immunosuppressants after a certain period of time," explains Dr. Felix Bohne, lead scientist of the study. Patients must take these strong drugs after transplants. They suppress the immune system so that the body does not identify the new organ as foreign and reject it. For patients with hepatitis C, this is a particular burden, as they need a stable immune system after the transplant to control their chronic HCV infection.

Markers for tolerance

During the study, the patients stopped taking the immunosuppressants. They were observed for twelve months to see which of them could also tolerate the new organ without the drugs, and which of them did not. The scientists took liver and blood samples from the patients prior to and after the cessation of the drugs. Detailed immunological tests on these patient samples were carried out under the leadership of Prof. Ulrike Protzer of the "Immunmonitoring Platform" at the Institute of Virology. The scientists compared the patients with each other and looked for any differences that arose in tolerant patients only.

And the scientists struck gold: a certain group of genes was very active only in the livers of tolerant patients. The genes in question belonged to the type I interferon system, which targets viruses like HCV as part of the innate immune system. As the results showed, an anti-viral mechanism does actually enable the patients to better tolerate a foreign organ.

Ulrike Protzer provides a possible explanation for this: "When the interferon system is constantly activated as is the case in some chronically-infected patients, it downregulates other immune reactions in order to protect the body. This state could act like a natural immunosuppressant and reduce the rejection of the organ."

In addition to the genes of the type I interferon system, a second factor was considered as a possible marker. This was discovered by the researchers in a previous study on liver recipients who did not have a HCV infection. Patients were very likely to be tolerant if they had a certain ratio of two different subgroups of immune cells in their blood. This ratio was also a reliable predictor of tolerance in the new study involving HCV patients.


'/>"/>

Contact: Vera Siegler
vera.siegler@tum.de
49-892-892-2731
Technische Universitaet Muenchen
Source:Eurekalert

Related biology news :

1. Studies reveal structure of EV71, a virus causing childhood illnesses
2. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
3. To drive infections, a hijacking virus mimics a cells signaling system
4. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
5. Harmless human virus may be able to boost the effects of chemotherapy
6. Researchers identify Achilles heel of dengue virus, target for future vaccines
7. Recapitulation of the entire hepatitis C virus life in engineered mouse cell lines
8. BGI, GMU, Mass. Eye and Ear and OUHSC announce agreement to sequence 100 human adenoviruses
9. Berkeley Lab scientists generate electricity from viruses
10. Virus barcodes offer rapid detection of mutated strains
11. Army study: DNA vaccine and duck eggs protect against hantavirus disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being enlisted ... bacteria that live in and on the human body –and are believed ... The Microbiome Immunity ... human microbiome, starting with the gut. The project's goal is to help ... credit: IBM ...
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology: